Ind-Swift Laboratories is currently trading at Rs. 100.00, up by 1.35 points or 1.37% from its previous closing of Rs. 98.65 on the BSE.
The scrip opened at Rs. 100.00 and has touched a high and low of Rs. 100.20 and Rs. 99.50 respectively. So far 6,073 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 133.00 on 08-Feb-2012 and a 52 week low of Rs. 74.50 on 26-Aug-2011.
Last one week high and low of the scrip stood at Rs. 100.45 and Rs. 92.30 respectively. The current market cap of the company is Rs. 331.00 crore.
The promoters holding in the company stood at 46.69% while Institutions and Non-Institutions held 4.81% and 48.44% respectively.
Pharma major Ind-Swift Laboratories has added another achievement into its credit by getting the USFDA approval for its five Active Pharmaceutical Ingredients (APIs) manufactured at its Derabassi manufacturing facility. With this approval, the company has entered in the league of big pharma majors having multi product approval for its facilities.
The facilities of the company were inspected in mid 2011. The Derabassi manufacturing facility of the company is one of the largest API manufacturing facilities in northern India. The products for which company has got the approval are - Naratriptan Hydrochloride (Anti-migraine), Ropinirole Hydrochloride (Anti-Parkinson's disease), Donepezil Hydrochloride (Anti-Alzheimer's disease), Acamprosate Calcium (Anti-alcohol dependence) and Clarithromycin (Macrolide Antibiotic).
Further, the worldwide market for these products is $5 billion. The company’s Derabassi facility is already accredited by key accreditation AGENCIES like TGA, MHRA, COS, KFDA and PMDA. With this approval the company will be able to sell its products to US market.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1517.90 |
| Dr. Reddys Lab | 6362.00 |
| Cipla | 1478.90 |
| Zydus Lifesciences | 1066.95 |
| Lupin | 1614.95 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
